Novartis Makes Plans to Release Four New Cancer Drugs by 2011 Dec 6, 2007
Others drugs Novartis aims to launch by 2011 are ASA404 for non-small-cell lung cancer, SOM230 for a rare group of neuroendocrine tumors and LBH589 for cutaneous T-cell lymphoma. The experimental drugs could fail in human tests or be rejected by regulators, including the U.S. Food and Drug Administration. (Wall Street Journal)
Radnor pharmaceutical company gets $14.5M in funding Nov 27, 2007
Yaupon is developing possible treatments for T-cell lymphoma, addiction and pain. The company's lead drug is Clearazidea, a topical agent for cutaneous T-cell lymphoma. (Philadelphia Business Journal, PA)
Top 10 Stocks Under $10 Oct 29, 2007
Biocryst told Wall Street on Oct. 12 that it has initiated enrollment of the trial of its lead oncology drug candidate, forodesine HCL, in the treatment of patients with cutaneous T-cell lymphoma (CTCL). The multinational trial will be conducted under a special agreement between the U.S. Food and Drug Administration and BioCryst. (Forbes)
Celiac Disease Oct 25, 2007
Enteropathy-Associated T-Cell Lymphoma. Refractory Celiac Disease. (New England Journal of Medicine)
BioCryst enrolling patients to test cancer drug Oct 13, 2007
is enrolling patients with T-cell lymphoma to test its cancer drug forodesine HCL. ... Eligible patients are those with T-cell lymphoma whose symptoms are persistent, progressive or recurrent during or after treatment. (Birmingham Business Journal)
Have you been misdiagnosed? Sep 20, 2007
Her doctor assured her it was right: two labs had confirmed the subcutaneous panniculitis-like T-cell lymphoma. Against her doctor's orders, Torrey delayed chemo and went to another oncologist, who sent a tissue sample to the National Institutes of Health. (CNN)
Physician, Heal Thyself Sep 11, 2007
On the blog now: Updated at 6:37 AM. Updated: 1:07 AM 09/11/07. (Townhall.com)
FACES OF HOPE Aug 27, 2007
He became an American immigrant success story, graduating with honors from Harvard Medical School and pioneering T-cell lymphoma research. About half of lymphoma patients can be cured or have their cancer sent into remission, as long as they get the right treatment from the start, he said. (Las Vegas Sun)
• Aetna Leader: A Proven Fighter Aug 26, 2007
The journey began when Eric was 16 and diagnosed with Gamma Delta T-cell lymphoma, a type of cancer of the T-cells, which are supposed to protect the body from infection. The cancer spread to his lymph nodes and bone marrow. (FOX61, CT)
Allos Therapeutics Reports Second Quarter 2007 Financial Results Aug 7, 2007
The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 trial in patients with relapsed or refractory peripheral T-cell lymphoma. The Company is also investigating PDX in patients with non small cell lung cancer and a range of other lymphoma sub-types. (Canada Newswire)
Rates of Lymphoma Increase Over 30 Years Jul 20, 2007
Chicago, IL - infoZine- Cutaneous T-cell lymphoma occurs when certain cells of the lymph system (called T lymphocytes) become cancerous and affect the skin ... D., of the VA Medical Center, Rhode Island Hospital, and Brown University, Providence, R.I., used data from 13 cancer registries of the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute to describe incidence trends in cutaneous T-cell lymphoma from 1973 through 2002 ... Scientists have been... (Kansas City infoZine)
Rates of Rare Lymphoma Increasing Jul 20, 2007
THURSDAY, July 19 (HealthDay News) -- The incidence of a rare cancer called cutaneous T-cell lymphoma has increased threefold over the past 30 years in the United States, a new study found ... The reasons for this dramatic increase in the rates of cutaneous T-cell lymphoma aren't known, Criscione said ... In cutaneous T-cell lymphoma, cells of the lymph system called T lymphocytes become cancerous, affecting the skin. (Health-Finder)
Cutaneous T-cell Lymphoma On The Rise, Research Shows Jul 18, 2007
Cutaneous T-cell lymphoma, a rare and mysterious cancer, is on the rise, according to the first nationwide study of the disease in a decade. The study, conducted by researchers at the Providence VA Medical Center and The Warren Alpert Medical School of Brown University, found that 4,783 new cases of cutaneous T-cell lymphoma were diagnosed between 1973 and 2002, the period under review ... Cutaneous T-cell lymphoma is caused by the uncontrolled growth of a type of white blood cell within the... (Science Daily)
BioCryst Pharmaceuticals Inc. Jul 10, 2007
The clinical trial, expected to start during the third quarter of 2007, is intended to determine the success rate of the drug that is taken orally to treat cutaneous T-cell lymphoma leukemia. The proposed trial will enroll patients with certain stages of T-cell lymphoma leukemia that is persistent, progressive or recurrent after treatment with at least three systemic therapies. (Birmingham Business Journal, AL)
Heern’s standing ovation was about more than just a free throw Jun 19, 2007
Ross Heern spent November through January in St. Jude s Children s Hospital after being diagnosed Nov. 1, 2006, with non-Hodgkin s lymphoblastic T-cell lymphoma a cancer of the immune system ... They did a needle biopsy, and on Nov. 1, they told us he had non-Hodgkin s lymphoblastic T-cell lymphoma. (West Frankfort Daily American, IL)
It Doesnt take Wealth to Leave an Inheritance Jun 16, 2007
Later, as a civilian physician, he was stunned to learn he suffers from a rare T-cell lymphoma, which his physician blames on exposure to TCE. Past contaminated water at Camp Lejeune is suspected in the death and illness of military and their families. (AP Photo/Gros Family). (Townhall.com)
Hope riding on NY marijuana bill Jun 15, 2007
"If something could help someone in severe pain, why should they be denied it?" said Greene, who also has T-cell lymphoma, a form of blood cancer. "I don't think the government has the right to make that choice.". (Newsday)
Nonresponsive Celiac Disease Due to Inhaled Gluten Jun 14, 2007
Adherence to diet is crucial for intestinal mucosal recovery, relief of symptoms, and prevention of intestinal T-cell lymphoma. 1 The amount of gluten needed to cause mucosal injury varies. (New England Journal of Medicine)
Marine Families Want $4B for Toxic Water Jun 13, 2007
Later, as a civilian physician, he was stunned to learn he suffers from a rare T-cell lymphoma, which his physician blames on exposure to TCE.. Gros's weak immune system now keeps him home. (Fox News)
Health Officials Hope a Study Will Reveal The Cause. Jun 12, 2007
He suffers from a rare T-cell lymphoma, which his physicians blame on exposure to TCE. ... Later, as a civilian physician, he was stunned to learn he suffers from a rare T-cell lymphoma, which his physician blames on exposure to TCE.. (The Ledger)
ECP may be effective in treating Crohn's disease May 26, 2007
The Therakos UVAR"XTS instrument, in conjunction with 8-methoxypsoralen, is the only ECP system approved by the Food and Drug Administration for the palliative treatment of the skin manifestations of Cutaneous T-cell Lymphoma that is unresponsive to other forms of treatment. The UVAR"XTS is also the only device in Europe that is CE marked for ECP.. ECP as performed on UVAR" systems has an established safety profile and more than 500,000 treatments have been conducted since 1987. The most... (EurekAlert!)
Orbiting factories take off May 7, 2007
" Too bad it didn't work out that way. The shuttle never lived up to the expectations of Stein and others, and there is still no low-cost way to get payloads and people into space. Yet in spite of all the disappointments, there are signs that the long-awaited space manufacturing revolution may finally be ready to take off. One of the original justifications NASA used for building the space station in the mid-1980s was that it would provide a unique environment for certain types of specialized... (San Francisco Chronicle -- Opinion)
Relay for Life looms with two honorary members chosen May 4, 2007
In November 2006 the Heern family of Thompsonville Illinois saw their otherwise normal life turned upside down when their son, Ross, was diagnosed with a form of Hodgkins T-Cell Lymphoma. What began as a visit to a local clinic on a Tuesday afternoon, to have a doctor examine Ross for some shortness of breath he was experiencing while running cross country for Thompsonville High School, became a fight for his life. (West Frankfort Daily American, IL)
Massey researchers induce cell death in leukemia Apr 17, 2007
Gloucester Pharmaceuticals is conducting a pivotal phase II study of romidepsin for patients with cutaneous T-cell lymphoma (CTCL) and has initiated a pivotal phase II study for patients with peripheral T-cell lymphoma (PTCL). Romidepsin has received Orphan Drug Designation from the Food and Drug Administration (FDA) for the treatment of non-Hodgkin T-cell lymphomas, which includes CTCL and PTCL. In addition, the European Agency for the Evaluation of Medicinal Products (EMEA) has issued Orphan... (EurekAlert!)
Transgene, Roche Enter Potential $293M Alliance On HPV Vaccine Apr 14, 2007
And TG 1042, an adenovector virus-based product delivering interferon gamma, is in Phase II trials for cutaneous T-cell lymphoma. Transgene intends to keep rights to that product, which addresses a smaller market, he said. (BioWorld Online)
BioCryst halts trial of cancer drug Mar 28, 2007
Stonehouse said BioCryst will channel resources to using Fodosine to treat cutaneous T-cell lymphoma, or CTCL. That could provide the fastest route to marketing approval of the drug, he said. "The results in treatment of CTCL with the oral formulation of Fodosine remain encouraging and we believe that this decision will allow us the greatest chance of getting Fodosine to a larger number of patients quickly," Stonehouse said. (Birmingham Business Journal)
When a popular North Stafford High School baseball player got cancer, the school community stepped up to help him. Feb 27, 2007
Soon after he recovered, he found a lump on his neck that turned out to be T-cell lymphoma. The aggressive cancer affects cells that fight infection. (Fredericksburg.com, VA)
Keep Going Hall of Famers - exhibit determination, perseverance, can-do attitude Feb 20, 2007
After Nicholas Marriam of Clayton, N.C., finished his treatment for T-Cell Lymphoma cancer, he decided he could help other kids going through the same thing. He started a local effort to deliver gift bags along with hope and courage to hospitalized children. (McKinney Courier-Gazette, TX)
BioCryst lymphoma drug takes step toward European market Feb 7, 2007
Fodosine, BioCryst's lead oncology candidate, is currently in clinical trials for the treatment of cutaneous T-cell lymphoma (CTCL). The EMEA's Committee for Orphan Medicinal Products put Fodosine on track toward the European market. (Birmingham Business Journal)
Ontario to treat autoimmune disorders Jan 19, 2007
The photopheresis machines will treat patients with chronic post-transplant graft versus host disease who have failed to benefit from other treatments, in addition to those with advanced, cutaneous T-cell lymphoma that is resistant to treatment, an Ontario government source said last night. The government provided funding to purchase the new two machines after a recommendation received from the Ontario health technology advisory committee. (Globe and Mail -- National)
Protection against cancer may begin during pregnancy Dec 22, 2006
In laboratory studies, researchers exposed pregnant mice to a single high dose of one PAH called dibenzopyrene, a potent carcinogen, and about 80 percent of their 100 offspring died early in life from an aggressive T-cell lymphoma. Of those that survived to the mouse-equivalent of middle age, 100 percent had lung tumors. (EurekAlert!)
Genmab Announces Early Results of Ongoing HuMax-CD4 Trials Dec 11, 2006
COPENHAGEN, Denmark, Dec. 10 /PRNewswire/ -- Genmab A/S (CSE: GEN) announced today positive early results of the first stage of the ongoing pivotal Phase III study of HuMax-CD4(R) (zanolimumab) in cutaneous T-cell lymphoma (CTCL) and the ongoing Phase II study in non-cutaneous T-cell lymphoma (NCTCL) ... "We are encouraged by the response rates in these patients who have failed other therapies." Preliminary results in the ongoing Phase II clinical trial in HuMax-CD4 to treat non-cutaneous T-cell... (PR Newswire)
MedImmune's Advancing Cancer Pipeline to Be Highlighted at the American Society of Hematology's Annual Meeting Dec 10, 2006
Data to be presented at ASH include: * "Update on Phase 1 Clinical Trial of IPI-504, a Novel, Water-Soluble Hsp90 Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma" (Abstract 3579, presented in a poster session, "Myeloma: Novel Agents and Toxicities," on Monday, Dec. 11 at 10:30 a.m.) * "A Phase 1 Open Label Dose Escalation Study To Evaluate MEDI-507 in Patients with CD2-Positive T-Cell Lymphoma/Leukemia" (Abstract 2727, presented in a poster session, "Novel and Targeted Therapy... (PR Newswire)
Significant Data on VELCADE(R) (bortezomib) For Injection To Be Presented at Upcoming American Society of Hematology Meeting Dec 9, 2006
D., UCLA Medical Center, Los Angeles, California * Final results of a Phase II study with weekly and twice-weekly VELCADE plus rituximab in relapsed/refractory follicular and marginal zone lymphomas B-cell Non-Hodgkin's Lymphoma (Abstract #2759, Sunday 10th December, 9:00 a.m.), Lead Investigator: John Gerecitano, M.D., Memorial Sloan-Kettering Cancer Center, New York, New York * Final results of a Phase I study of VELCADE plus rituximab, cyclophosphamide and prednisone (R-CVP) in... (PR Newswire)
Senior at T-ville High School to get help from locals Dec 9, 2006
The young man was immediately sent to the Children's Hospital in Memphis TN. Upon his arrival there he underwent the necessary tests and was diagnosed with Non-Hodgkin's T-Cell Lymphoma. The Doctors immediately started Chemotherapy treatments and Ross and his family have remained in Memphis. (West Frankfort Daily American, IL)
FDA Approves Merck Cancer Drug Oct 31, 2006
The Food and Drug Administration has approved Merck s drug Zolinza, a treatment for a rare skin cancer called cutaneuous T-cell lymphoma ... However, most patients with cutaneuous T-cell lymphoma are men with an average age of 50 years. (Forbes)
FDA CAPSULES Oct 17, 2006
DRUG FOR RARE TYPE OF SKIN CANCER. Zolinza has been approved to treat cutaneous T-cell lymphoma, a rare skin cancer diagnosed in about three in every 1 million people yearly in the United States. Zolinza was approved under the FDA's orphan drugs program, which provides financial incentives to companies that develop treatments for diseases that affect fewer than 200,000 U.S. patients per year. (Newsday -- Health)
Mr. T leads new A(dvice)-team Oct 13, 2006
In 1982, Sylvester Stallone saw him on television in the "World's Toughest Bouncer" contest and offered him the role of boxer Clubber Lang in Rocky III. Mr. T then played Sgt. Bosco "B.A." Baracus on The A-Team, which ran from 1983 to 1987 on NBC. Mr. T was diagnosed with T-cell lymphoma in 1995, but his bio says he is cancer-free today. He speaks frequently about his mother, which makes me wonder if he lives with his mother. (Orlando Sentinel -- Entertainment)
Mr. T, consultant Oct 11, 2006
But it turned out to be T-cell lymphoma. Forbes: In the first episode of your new series, you shape up a car dealership that's in the doldrums. (MSNBC -- Business)
Merck says FDA approves Zolinza for lymphoma Oct 10, 2006
Merck said the U.S. Food and Drug Administration approved the treatment, called Zolinza, for patients with cutaneous T-cell lymphoma for those with progressive, persistent or recurrent forms of the disease. Sponsored Links. (San Diego Union-Tribune -- Business)
US OKs new Merck drug for rare skin cancer Oct 7, 2006
The once-a-day oral drug called Zolinza was approved for use when advanced cutaneous T-cell lymphoma (CTCL) persists, worsens or returns during or after treatment with other medicines, the U.S. Food and Drug Administration said. CTCL occurs in about three out of every 1 million people in the United States, the FDA said. (Reuters.uk)
FDA Approves New Drug for Skin Cancer, Zolinza Oct 7, 2006
The U.S. Food and Drug Administration (FDA) today approved Zolinza (vorinostat) capsules for the treatment of cutaneous T-cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. Zolinza was approved as part of FDA's Orphan Drug program, which offers companies financial incentives to develop medications for diseases affecting fewer than 200,000 American patients a year. (U.S. Food and Drug Administration)
Merck cancer drug approved Oct 7, 2006
The Food and Drug Administration approved the drug, Zolinza, to treat advanced cases of cutaneous T-cell lymphoma, a rare cancer that's a form of non-Hodgkin's lymphoma. The drug is to be used when the disease persists, gets worse or comes back during or after treatment with other medicines, the FDA said. (International Herald Tribune)
Talking with Mr. T Oct 7, 2006
Maybe that's from being a cancer survivor, diagnosed with T-cell lymphoma in 1995 at age 43. Maybe it's from growing up one of 12 children in the Robert Taylor Homes housing project on Chicago's South Side. (Newsday -- Entertainment)
Eisai Buys Rights to Four Cancer Drugs From Ligand for About $205 Million Sep 8, 2006
It gives Eisai global rights to ONTAK and Targretin capsules, both of which are used to treat patients with skin lesions caused by persistent or recurrent cutaneous T-cell lymphoma. The agreement also covers rights to a gel version of Targretin, and a gel version of Panretin, used to treat skin lesions in patients with AIDS-related Kaposi's sarcoma. (Bloomberg -- Japan)
O'Connor's doctor: Nothing tamed mayor's raging cancer Sep 6, 2006
On July 10, Mr. O'Connor's medical team, led by Dr. Marks, announced that he had T-cell lymphoma of the brain, although the diagnosis had been confirmed three days earlier, on a Friday ... Dr. Paul Zeltzer, a professor of neurosurgery at the University of California, Los Angeles, said he has been involved in treating just two patients with primary CNS T-cell lymphoma, one who responded to treatment and one who did not. (Pittsburgh Post-Gazette, PA)
Index: Recent coverage Sep 5, 2006
Pittsburgh Mayor Bob O'Connor died Sept. 1, ending a two-month battle with primary central nervous system T-cell lymphoma, an unusual cancer of the brain and spinal cord. Mr. O'Connor, 61, a former City Council president had sought the mayor's post for 12 years before being elected in 2005. (Pittsburgh Post-Gazette, PA)
Mayor given respite from treatments Aug 26, 2006
As the mayor continued his battle against primary central nervous system T-cell lymphoma yesterday, the outpouring of support for his recovery remained strong. In less than a day, The Leukemia & Lymphoma Society sold a second batch of 5,000 wristbands at seven locations around the city, according to Maureen Durkin, the organization's spokeswoman. (Pittsburgh Post-Gazette, PA)
Doctors see improvement in Mayor O'Connor Aug 19, 2006
Mr. O'Connor, who was diagnosed with primary central nervous system T-cell lymphoma last month, had his second treatment of whole-brain radiation yesterday afternoon. He is not expected to have any treatments over the weekend. (Pittsburgh Post-Gazette, PA)
Mayor Bob O'Connor Aug 17, 2006
Dr. Stanley Marks, director of clinical services at UPMC Hillman Cancer Center, said the high-dose methotrexate treatments the mayor has been getting every two weeks since July 11 to treat primary central nervous system T-cell lymphoma have greatly reduced the number of cancer cells in his spinal fluid ... Because this type of T-cell lymphoma is so rare, it's hard to predict treatment response, said Dr. Michael Robertson, director of the lymphoma program at the Indiana University Cancer Center... (Pittsburgh Post-Gazette, PA)
Doctors uncertain of O'Connor's prognosis Aug 8, 2006
He was diagnosed July 10 with primary central nervous system T-cell lymphoma. "Right now, we're taking things day to day," Dr. Lieberman said. (Pittsburgh Post-Gazette, PA)
Reaction to cancer treatment varies from patient to patient Jul 25, 2006
T-cell lymphoma "is a pretty aggressive type of tumor," Dr. Stark-Vance said. "But sometimes, the more aggressive the tumor, the easier it is to treat," because of the distinctive behavior of the cancer cells. (Pittsburgh Post-Gazette, PA)
Malachi Thompson, 56; Jazz Trumpeter, Composer and Arts Activist Jul 20, 2006
After returning to Chicago, he was diagnosed with T-cell lymphoma in 1989. While receiving treatment, Thompson studied jazz history and wrote the musical play "The Jazz Life," which premiered in 1990. (Los Angeles Times)
Obituaries in the News Jul 19, 2006
Doctors told Thompson in 1989 that he had a year to live after being diagnosed with T-cell lymphoma. Thompson later said the diagnosis transformed his music and led him to release "Lift Every Voice" in 1993, which explored the roots of black musical culture. (The Ledger)
Expert makes lymphoma treatment his life's pursuit Jul 10, 2006
"He told me, 'You're in the garbage can.' I asked him why, and he said the type of cancer I had -- peripheral T-cell lymphoma -- was hard to identify," Fitzwilson said. "It was very complicated but he explained it to me in a way that I could understand. Then he told me what my options were.'' Fitzwilson said he visited Dang again in May to go over those options. Three weeks ago, he began his first treatment. "The fact that I had to go outside California speaks volumes about my experience in... (Las Vegas Review-Journal -- Nevada News)
A Ligand Is Reborn Jun 17, 2006
The San Diego company's products include Avinza, an oral morphine for the treatment of moderate to severe pain; Ontak, which treats T-cell lymphoma; Targretin capsules and gel for the treatment of refractory cutaneous T-cell lymphoma; and Panretin gel, for the treatment of Kaposi's sarcoma in AIDS patients. It's also expanding indications for its marketed products. (SmartMoney)
Researchers Report New Molecule That Targets Leukemia And Lymphoma Cells Jun 14, 2006
These antibodies have drawbacks, however: They bind to healthy lymphocytes along with malignant ones; in addition, they do not bind to T cells and therefore can't be used to treat T-cell lymphoma. In contrast, LLP2A binds to both B-cell and T-cell lymphoid cancer lines, and has low affinity for normal T or B lymphocytes. (Science Daily)
First cancer vaccine could revive Merck Jun 12, 2006
A recent early-stage trial of Zolinza, a drug being developed to treat cutaneous T-cell lymphoma, included 74 patients. When you want to prove efficacy (of a vaccine), Block explained, how do you do that. (phillyBurbs.com)
Alemtuzumab in Refractory Celiac Disease Jun 8, 2006
NEJM -- Alemtuzumab for Refractory Celiac Disease in a Patient at Risk for Enteropathy-Associated T-Cell Lymphoma ... Alemtuzumab for Refractory Celiac Disease in a Patient at Risk for Enteropathy-Associated T-Cell Lymphoma. (New England Journal of Medicine)
FDA Approves REMICADE(R) as First and Only Biologic Treatment for Children With Active Crohn's Disease May 20, 2006
Along with this approval, Centocor, in consultation with FDA, has added to the boxed warning in the labeling for REMICADE a description of rare post- marketing cases of hepatosplenic T-cell lymphoma that have been reported in adolescents and young adults with Crohn's disease (see Important Safety Information below and the full prescribing information available at ). Approximately 100,000 children under the age of 17 suffer from inflammatory bowel diseases (IBD), which include CD and ulcerative... (PR Newswire)
FDA Approves Remicade for Children with Crohn’s Disease May 20, 2006
More recently, the FDA has received rare post-marketing reports of an aggressive and often fatal type of T-cell lymphoma (hepatosplenic T-cell lymphoma) in adolescent and young adult patients with the Crohn's disease. In most, but not all cases, these patients were treated with standard immunosuppressive therapies (azathioprine or 6-mercaptopurine) in combination with Remicade. (U.S. Food and Drug Administration)
BioCryst Reports Fourth Quarter and Year-End 2005 Financial... Feb 8, 2006
"Additionally," said Dr. Bugg, "We are studying an oral formulation of Fodosine(TM) in a Phase I trial targeting cutaneous T-cell lymphoma (CTCL) and a Phase II trial in chronic lymphocytic leukemia (CLL). In December of 2005, we initiated a Phase I/II trial of intravenous Fodosine(TM) in B-cell acute lymphoblastic leukemia (B-ALL)." ... This year is expected to be equally exciting and we are eager to continue to move our corporate and clinical programs forward," said Dr. Bugg. Conference Call... (CNBC -- Research Alerts)
